Literature DB >> 21707594

Management of inherited thrombophilia: guide for genetics professionals.

E A Varga1, J L Kujovich.   

Abstract

Venous thromboembolism (VTE) is a common source of morbidity and mortality in developed countries. Heritable risk factors for VTE (thrombophilias) can be identified in 30-50% of affected patients. Factor V Leiden, prothrombin 20210G>A, and deficiencies of antithrombin, protein C and protein S increase the risk of a first VTE. However, an individual's thrombotic risk is determined by a complex interplay of genetic, acquired and circumstantial risk factors. At least 50% of VTE events in thrombophilic individuals are provoked by predisposing factors such as immobility, surgery, trauma, cancer, hormonal therapy and pregnancy. Non-modifiable risk factors such as advancing age and family history also increase thrombotic risk. An evidence-based risk factor evaluation is an essential step in VTE prevention. This review will educate genetics professionals about inherited and acquired risk factors for VTE and discuss recommendations for management of asymptomatic individuals with thrombophilia.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707594     DOI: 10.1111/j.1399-0004.2011.01746.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

1.  Prevalence of 1691G>A FV mutation in females from Bosnia and Herzegovina--a preliminary report.

Authors:  Amina Valjevac; Bakir Mehić; Emina Kiseljaković; Slavka Ibrulj; Agnieszka Garstka; Grażyna Adler
Journal:  Bosn J Basic Med Sci       Date:  2013-02       Impact factor: 3.363

2.  A clinical approach to inherited premature coronary artery disease.

Authors:  Nathan O Stitziel; Calum A MacRae
Journal:  Circ Cardiovasc Genet       Date:  2014-08

3.  The Prevalence of the Prothrombin (F2) 20210G>A Mutation in a Cohort of Sri Lankan Patients with Thromboembolic Disorders.

Authors:  K M D Gunathilake; U N D Sirisena; P K D Nisansala; H W W Goonasekera; R W Jayasekara; V H W Dissanayake
Journal:  Indian J Hematol Blood Transfus       Date:  2014-09-02       Impact factor: 0.900

4.  Association of interleukin-18 gene polymorphism and its protein expression with the lower extremity deep venous thrombosis in the chinese han population: A case-control study.

Authors:  Ye-Long Chen; Li-Hong Shou; Zong-Xin Zhang
Journal:  J Clin Lab Anal       Date:  2017-11-04       Impact factor: 2.352

5.  Multilocus genetic risk scores for venous thromboembolism risk assessment.

Authors:  José Manuel Soria; Pierre-Emmanuel Morange; Joan Vila; Juan Carlos Souto; Manel Moyano; David-Alexandre Trégouët; José Mateo; Noémi Saut; Eduardo Salas; Roberto Elosua
Journal:  J Am Heart Assoc       Date:  2014-10-23       Impact factor: 5.501

6.  Apolipoprotein E polymorphism is associated with lower extremity deep venous thrombosis: color-flow Doppler ultrasound evaluation.

Authors:  Shuangli Zhu; ZhiGang Wang; XiaoPing Wu; Yan Shu; DunXiang Lu
Journal:  Lipids Health Dis       Date:  2014-01-24       Impact factor: 3.876

7.  Ultrasound screening for deep venous thrombosis detection: a prospective evaluation of 200 plastic surgery outpatients.

Authors:  Eric Swanson
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-04-07

8.  Caprini Scores, Risk Stratification, and Rivaroxaban in Plastic Surgery: Time to Reconsider Our Strategy.

Authors:  Eric Swanson
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-06-13

9.  An Uncommon Case of Lower Limb Deep Vein Thrombosis with Multiple Etiological Causes.

Authors:  Jing Miao; Geetha Naik; Sivakumar Muddana; Xiaohuan Li; Supriya Bhimasani; Ronald Alvin Mitchell; Dariush Alaie; Richard L Petrillo
Journal:  Am J Case Rep       Date:  2017-03-28

10.  Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions.

Authors:  Pushpinderdeep Kahlon; Shahzaib Nabi; Adeel Arshad; Absia Jabbar; Ali Haythem
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.